Petros Pharmaceuticals, Inc. Cash and Restricted Cash
Petros Pharmaceuticals, Inc. (PTPI) had Cash and Restricted Cash of $3.49 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.49M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.35M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.14M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.07M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $3.49M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $4.35M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $5.14M 10-K · filed 2026-04-15 | |
| 2025-09-30 | $6.07M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $7.32M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $8.93M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $1.72M 10-K · filed 2026-04-15 | $3.71M 10-K · filed 2025-03-31 |
| 2024-09-30 | $3.20M 10-Q · filed 2025-11-13 | $3.89M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $6.75M 10-Q · filed 2025-08-14 | $7.46M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $10.28M 10-Q · filed 2025-05-15 | $11.08M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $13.34M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $17.97M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $7.38M 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $8.32M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $9.43M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $11.18M 10-Q · filed 2023-11-15 | |
| 2022-06-30 | $13.30M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $17.67M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $23.85M 10-K · filed 2024-04-01 | |
| 2021-09-30 | $8.14M 10-Q/A · filed 2022-11-15 | |
| 2021-06-30 | $11.03M 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $14.57M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $17.14M 10-K · filed 2023-03-31 | |
| 2020-09-30 | $669.08K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $831.76K 10-Q · filed 2021-08-16 | |
| 2020-03-31 | $1.14M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $2.15M 10-K · filed 2022-03-31 | $2.15M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |